Acute respiratory distress syndrome(ARDS)is a clinical syndrome characterized by refractory hypoxemia and progressive dyspnea. It is one of the leading causes of death in critically illed patients. In recent years

although the rapid development of medical technology and the application of new drugs have improved the prognosis of ARDS

the mortality of ARDS is still as high as 40%-50%. Therefore

it is still the focus and hotpot in the research of respiratory and intensive medicine to further understand the pathogenesis of ARDS

achieve early diagnosis

and provide guidance for the prevention and treatment of ARDS. Interleukin-33(IL-33)is a recently discovered member of the Interleukin-1(IL-1)family. It plays a crucial role as an alarmins in inflammation

infection

au toimmune disease and many other diseases

enlarges the body’s inflammatory response

and aggravate tissue injury. Therefore

IL-33 and its signal pathway probably become potential molecular targets to block the cascade of inflammatory pathways in the treatment of ARDS. In this paper

we reviewed on the role of IL-33 in ARDS.